📇 Rhumatologue · GAP · (05) · Libéral

M IVAN PROTHOY

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Auteur de référence en rhumatologie
28 articles scientifiques publiés — un praticien à la pointe de la recherche
Référence presse grand public
Cité 4 fois dans les médias — pédagogie reconnue
Délais de RDV courts dans la région
184.1 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 GAP (05)LibéralRPPS 10001468684

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

CABINET DU DR IVAN PROTHOY
POLYCLINIQUE ALPES DU SUD 3 RUE ANTONIN CORONAT, 05000 GAP
☎ 0826555001Activité de soin et de pharmacie

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Postnatal healing of cesarean scar: an ultrasound study

American journal of obstetrics and gynecology · 2026

📚 3 citations🩺 Clinique🔓 Open Access

Hybrid Therapy for Newly Diagnosed and Recurrent Glioblastoma: Staged Procedure Integrating Open Surgical Resection With Laser Interstitial Thermal Therapy

Operative neurosurgery (Hagerstown, Md.) · 2026

📚 1 citations

Lire l'abstract Crossref ↓

BACKGROUND AND OBJECTIVES: Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor in adults with a median overall survival of 15.6 months. Despite advancements, 5-year survival rates have not significantly improved. Laser interstitial thermal therapy (LITT) has been used to treat both newly diagnosed (nGBM) and recurrent GBM (rGBM) with demonstrable safety and efficacy. Traditionally, LITT has been limited to smaller lesions given physical and thermal constraints. We present 2 case examples of a novel, hybrid treatment approach to GBM, using both surgery and laser ablation as part of a staged procedure. METHODS: Two geriatric (older than 65 years) patients with nGBM or rGBM were treated with surgical resection followed by LITT the subsequent day. Both patients underwent preoperative MRI showing multifocal disease with a dominant component, causing mass effect in the second case, and an unresectable component. RESULTS: The first case underwent surgical resection of a large, multicentric rGBM in the parieto-occipital region, followed by LITT of an unresectable lesion in the inferior temporal gyrus. The second patient underwent surgical resection of the dominant temporal lobe component and LITT of the insular component. Neither patient had intraoperative or ablation complications. Both patients had stable postoperative neurological examinations and were discharged on the day after ablation, with no new deficits at follow-up. CONCLUSION: The prognosis for GBM remains dismal despite attempts at advancements in patient management. Surgical resection is a critical component of the GBM treatment paradigm, although, alone, is not sufficient for maximal therapeutics in many patients. LITT is a minimally invasive means of cytoreduction that has shown promise for improving GBM outcomes. We demonstrate a novel, hybrid approach to GBM using hybrid surgical resection and LITT in a staged procedure to overcome traditional constraints of both open resection or LITT alone.

Translating Venom to Medicine: A Comprehensive Review on the Role of Chlorotoxin in Glioblastoma Diagnosis and Therapy

Molecular cancer therapeutics · 2025

📚 1 citations

Lire l'abstract Crossref ↓

Abstract Glioblastoma, the most aggressive primary brain tumor, carries a dismal prognosis, with median survival remaining under 15 months despite standard therapies. This is largely because of the tumor’s infiltrative nature, the restrictive blood–brain barrier, and intratumoral heterogeneity. Chlorotoxin (CTX), a 36-amino acid peptide derived from scorpion venom, has emerged as a promising multifunctional agent with high specificity for neuroectodermal tumors. In this comprehensive review, we highlight CTX’s potential to address critical limitations of current glioma treatments by bridging diagnostic and therapeutic modalities. Diagnostic advancements include CTX-conjugated near-IF fluorophores and nanoparticles for fluorescence-guided surgery and multimodal imaging to enhance intraoperative accuracy. On the therapeutic front, CTX enables targeted delivery of siRNA, radioisotopes, and novel immunotherapies such as CTX-directed chimeric antigen receptor T cells. We also examine emerging clinical data supporting the safety and preliminary efficacy of CTX-based interventions. Collectively, CTX represents a paradigm shift in neuro-oncology, offering a single molecule with both diagnostic and therapeutic capabilities. Its utility may also extend beyond gliomas to metastases and other malignancies within and beyond the central nervous system.

Cookies & analyse de trafic

M IVAN PROTHOY

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Articles de presse (4)

Top publications · les plus citées

Publications scientifiques (28) — classées par pathologie

Transversal7

Revue générale6

Épidémiologie & registres4

Case report / série3

Pédiatrie3

Génétique2

Pharmacovigilance2

Revue / méta-analyse2

Gériatrie1

IA en rhumatologie1

IRM ostéo-articulaire1

Partager cette fiche